Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
7.96
-0.43 (-5.13%)
Apr 23, 2026, 2:24 PM EDT - Market open
Grifols Revenue
In the year 2025, Grifols had annual revenue of 7.52B EUR with 4.33% growth. Grifols had revenue of 1.98B in the quarter ending December 31, 2025, with 0.32% growth.
Revenue (ttm)
7.52B EUR
Revenue Growth
+4.33%
P/S Ratio
0.76
Revenue / Employee
298,016 EUR
Employees
25,247
Market Cap
6.73B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.52B | 312.00M | 4.33% |
| Dec 31, 2024 | 7.21B | 620.00M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.03M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
| Amgen | 36.75B |
| Gilead Sciences | 29.44B |
GRFS News
- 14 days ago - Manitoba medical examiner says investigations complete in deaths of plasma donors - CBC News
- 21 days ago - Grifols (GRFS) Faces Health Canada's New Regulations After Inspection Failures - GuruFocus
- 21 days ago - Health Canada slaps new conditions on plasma donation company Grifols, still reviewing 2 Manitoba deaths - CBC News
- 23 days ago - Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewsWire
- 4 weeks ago - Bullish Two Hundred Day Moving Average Cross - GRF - Nasdaq
- 4 weeks ago - Grifols (GRFS) Considers U.S. IPO Amid Strategic Shift - GuruFocus
- 4 weeks ago - Grifols (GRFS) Plans U.S. IPO for Biopharma Business - GuruFocus
- 4 weeks ago - Grifols Plans IPO of U.S. Biopharma Business - The Wall Street Journal